Long-term Impact of Infection With Novel Coronavirus (COVID-19)

Description

LIINC is a study of volunteers who were previously infected with SARS-CoV-2 (also known as novel coronavirus or COVID-19) who have recovered from acute infection. The study is designed to provide a specimen bank of samples with carefully characterized clinical data. LIINC specimens will be used to examine multiple questions involving the virologic, immunologic, and host factors involved in COVID-19, with a focus on understanding variability in the long-term immune response between individuals.

Conditions

COVID

Talk to us

Study Overview

On this page

Study Details

Study overview

LIINC is a study of volunteers who were previously infected with SARS-CoV-2 (also known as novel coronavirus or COVID-19) who have recovered from acute infection. The study is designed to provide a specimen bank of samples with carefully characterized clinical data. LIINC specimens will be used to examine multiple questions involving the virologic, immunologic, and host factors involved in COVID-19, with a focus on understanding variability in the long-term immune response between individuals.

Long-term Impact of Infection With Novel Coronavirus (LIINC): An Observational Study

Long-term Impact of Infection With Novel Coronavirus (COVID-19)

Condition
COVID
Intervention / Treatment

-

Contacts and Locations

San Francisco

Zuckerberg San Francisco General Hospital (ZSFG), San Francisco, California, United States, 94110

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Willing and able to provide written informed consent, and
  • 2. Age \>/= 18 years, and
  • 3. A history of SARS-CoV-2 infection, as evidenced by:
  • 1. Available laboratory documentation of SARS-CoV-2 RNA positivity on a nucleic acid amplification test or by serologic testing when this becomes available, or
  • 2. Reference by the participant to a laboratory test performed on respiratory tract secretions or blood, fingerstick, or saliva test that was reported to the participant to be positive for SARS-CoV-2 or COVID-19 infection,
  • 4. And a period of 21 days or more has elapsed since the first positive test or symptoms preceding the first positive test, whichever is earlier.
  • 1. Self-reported or documented chronic anemia with hemoglobin \< 9 g/dL. Anemia during a preceding acute illness will not be exclusionary.
  • 2. Serious medical or psychiatric illness that, in the opinion of the site investigator, would interfere with the ability to adhere to study requirements or to give informed consent.
  • 3. Active drug or alcohol use or dependence that, in the opinion of the Principal Investigator, would interfere with adherence to study requirements or to give informed consent.

Ages Eligible for Study

18 Years to 100 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, San Francisco,

Steven Deeks, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Michael J Peluso, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

2025-12-31